Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease

Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies

(2012) David S. Goldstein et al.   BRAIN

Stress, Allostatic Load, Catecholamines, and Other Neurotransmitters in Neurodegenerative Diseases

(2012) David S. Goldstein   CELLULAR AND MOLECULAR NEUROBIOLOGY

Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease

(2012) David S. Goldstein et al.   JOURNAL OF NEUROCHEMISTRY

A molecular signature in blood identifies early Parkinson’s disease

(2012) Leonid Molochnikov et al.   Molecular Neurodegeneration

Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons

(2012) Ayse Ulusoy et al.   NEUROBIOLOGY OF DISEASE

Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease

(2012) Margaret Chia-Ying Wey et al.   PLoS One

Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease

(2012) A. G. Fitzmaurice et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oxidation of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopaminergic Metabolite, to a Semiquinone Radical and anortho-Quinone

(2011) David G. Anderson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Distribution of Vesicular Monoamine Transporter 2 Protein in Human Brain: Implications for Brain Imaging Studies

(2011) Junchao Tong et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Contamination of the Norepinephrine Prodrug Droxidopa by Dihydroxyphenylacetaldehyde

(2010) C. Holmes et al.   CLINICAL CHEMISTRY

Catechols in post-mortem brain of patients with Parkinson disease

(2010) D. S. Goldstein et al.   EUROPEAN JOURNAL OF NEUROLOGY

Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease

(2010) Edna Grünblatt et al.   JOURNAL OF NEURAL TRANSMISSION

In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133

(2010) N. Okamura et al.   JOURNAL OF NUCLEAR MEDICINE

The Neurotoxicity of DOPAL: Behavioral and Stereological Evidence for Its Role in Parkinson Disease Pathogenesis

(2010) W. Michael Panneton et al.   PLoS One

Protein Reactivity of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite, Is Dependent on Both the Aldehyde and the Catechol

(2009) Jennifer N. Rees et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity

(2009) T. N. Taylor et al.   JOURNAL OF NEUROSCIENCE

Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons

(2009) Thomas S. Guillot et al.   MOLECULAR NEUROBIOLOGY

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

(2009) Wataru Satake et al.   NATURE GENETICS

Incidental Lewy Body Disease and Preclinical Parkinson Disease

(2008) Anthony DelleDonne et al.   ARCHIVES OF NEUROLOGY

Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis

(2008) Thomas S. Guillot et al.   JOURNAL OF NEUROCHEMISTRY

Proteome analysis of human substantia nigra in Parkinson's disease

(2008) Cornelius J Werner et al.   Proteome Science

Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism

(2008) Yan Sai et al.   TOXICOLOGY IN VITRO